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In recent years, there have been numerous advances in
understanding the molecular determinants of functional
kidney injury after ischemic and/or toxic exposure. However,
translation of successful novel therapies designed to
attenuate kidney functional injury from animal models to the
clinical sphere has had modest results. This lack of
translatability is at least in part due to lack of sufficient
standardization in definitions and classification of cases of
acute kidney injury (AKI), an incomplete understanding of the
natural history of human AKI, and a limited understanding of
how kidney injury interacts with other organ system failure in
the context of systemic metabolic abnormalities. A concerted
effort is now being made by nephrologists and intensivists to
arrive at standardized terminology and classification of AKI.
There have also been dramatic advances in our
understanding of the epidemiology and natural history of
AKI, particularly in the hospital and intensive care unit
setting. Promising strategies are now being developed which
may ultimately lead to improved outcomes for patients at risk
for or who have developed AKI, which should be readily
testable in the coming decade.
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LEXICOGRAPHY
The lexicography of what is now best termed acute kidney
injury (AKI) is richly related to many important historical
figures in the history of medicine and the study of kidney
diseases.1 It was William Heberden in his ‘Commentaries on
the History and Cure of Diseases’ who first described the
clinical course of AKI (then termed ‘ischuria renalis’) in 1802.
Bowman, Charcot, and William Osler all made important
contributions. However, the syndrome was largely overlooked
until Bywaters and Beal classically described anuric AKI after
crush syndrome during the German bombing of London
during WWII. Also during WWII, Andre Cournand (later
winner of the 1956 Nobel Prize in Physiology or Medicine)
and co-workers were the first to study extensively changes
in kidney function associated with circulatory failure or
shock in man during an investigation carried out at Bellevue
Hospital.
Perhaps, the modern era in the study of AKI truly began in
1951, when Homer W Smith introduced the term acute renal
failure in his seminal text ‘The Kidney – Structure and
Function in Health and Disease.’2 Smith comprehensively
reviewed data from animal models, as well as physiologic,
pathologic, and clinical data from human cases of acute renal
failure. Still of interest today, Smith provided clinical advice
for the treatment of anuria. ‘The treatment of anuria should
be conservative. If circulatory failure is present, appropriate
steps should be taken to correct it. Otherwise, therapy is
limited to the balanced maintenance of the patient until the
kidneys have a chance to affect recoveryyIt is now widely
recognized that a serious mistake of the past has been the
zealous overadministration of fluid on the theory that the
anuric patient was ‘dehydrated’yIt is easy to expand the
body fluids to such an extent as to produce dangerous
pulmonary edema and perhaps to promote the formation of
renal edema.yAlthough the artificial kidney, peritoneal
dialysis, replacement transfusion, and intestinal irrigation
are possibly useful in some cases in supporting the patient
through a critical period of uremia, the indications for their
use are not clearly defined. They cannot in themselves induce
diuresis and their value in influencing the course of acute
anuria, usually a self-limited disturbance, defies critical
evaluation. Because each method involves an inherent
physiologic burden, the application of any of them may
handicap rather than promote spontaneous recovery. The
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most notable aspect of this problem is the remarkable
capacity of the renal parenchyma to reconstitute itself after
devastating injury.’2
Homer Smith’s term acute renal failure stood the test of
time until the twenty-first century. Recently, a group of
international experts (comprised both nephrologists and
intensivists) have attempted to develop a broad consensus on
new definitions and terminology for acute renal failure. First
known as the Acute Dialysis Quality Initiative (ADQI) and
later as the AKI Network (AKIN), this group has proposed
the term ‘acute kidney injury’ to redefine the entire spectrum
of acute renal dysfunction, encompassing early and mild
forms all the way to severe forms requiring renal-replacement
therapy. This change in terminology was prompted by several
considerations, including:
1. The recognition that even relatively modest changes in
serum creatinine are highly associated with adverse
outcomes in hospitalized patients, this suggesting that
the syndrome should encompass more than outright
kidney failure;
2. Recognition that the term ‘injury’ more accurately
conveys the associated pathobiology than the term
‘failure’; and
3. Recognition that the English word ‘kidney’ is more
readily understood by the general public than the Latin-
derived word ‘renal.’
DEFINITIONS OF AKI
The desire to standardize the definition of AKI is prompted
by recognition that the published literature contains a
strikingly wide spectrum of definitions, making cross-
comparison between studies difficult (reviewed by Mehta
and Chertow).3 Indeed, in a recent survey, at least 35 separate
definitions of AKI were identified in the literature. To date, all
definitions of AKI have relied on either an abrupt increase in
serum creatinine (to denote a reduction in glomerular
filtration rate) or an abrupt decline in urine output. Recently,
tremendous interest has been generated in the development
of urinary and blood biomarkers that may be able to detect
early AKI before a rise in serum creatinine.4 However,
although several biomarkers hold great promise with respect
to the ability to create a new paradigm in the definition of
AKI, to date clinical biomarker studies have generally been
performed as single center studies and their positive and
negative predictive value have not been validated in multiple
heterogenous populations. Thus, for the present, definitions
and classification of AKI continue to revolve around changes
in serum creatinine and urine output.
A key element has been the emergence of data from
multiple studies demonstrating that relatively small decreases
in kidney function are prognostically important. Over a
decade ago, Levy et al.5 demonstrated that at 25% increase in
serum creatinine after exposure to radiocontrast material was
associated with greatly increased odds of death. In a study
using a hospital-wide database, any increase of serum
creatinine of greater than 0.3 mg/dl was independently
associated with increased costs and mortality risks (Table 1).6
Similar data have also been obtained in studies of AKI after
cardiac surgery and other cardiac conditions.7 These data
have spawned new definitions of AKI dependent on relatively
small changes in serum creatinine, thereby increasing the
prevalence of AKI.
The RIFLE (Risk, Injury, and Failure with the outcome
classes Loss and End-stage kidney disease) criteria combine
severity grades based on changes in serum creatinine or urine
output with clinical outcome criteria (Figure 1). Early studies
suggest that use of RIFLE criteria in the intensive care unit
(ICU) setting conveys significant prognostic information in
the majority of studies.8 More recently, the AKI network has
suggested a more simplified definition which depends only
on a greater than 0.3 mg/dl (425 mmol/l) rise or a 450%
increase in serum creatinine or the development of oliguria as
defined by urine output o0.5 ml/kg/h for greater than 6 h.
Table 1 | Hospital-acquired AKI: mortality and cost associated
with selected changes in SCr
Increase in SCr
(mg/dl)
Multivariable OR
(95% CI)
Area under
ROC curve
Increase in
total cost
0.3 4.1 (3.1–5.5) 0.84 $4,886
0.5 6.5 (5.0–8.5) 0.86 $7,499
1.0 9.7 (7.1–13.2) 0.84 $13,200
2.0 16.4 (10.3–26) 0.83 $22,023
AKI, acute kidney injury; CI, confidence interval; OR, odds ratio; ROC, receiving
operating characteristic; SCr, serum creatinine.
Non-oliguria
Abrupt (1–7) days decrease
(>25% in GFR, or
serum creatinine × 1.5
sustained
Adjust creatinine or
GFR decrease > 50%
serum creatinine × 2
Adjust creatinine or
GFR decrease > 75%
serum creatinine × 3 or
serum creatinine >4 mg%
when acute
increase >0.5 mg%
Decreased UO relative
to fluid input
UO <0.5 mg/kg/h × 6 h
UO <0.5 mg/kg/h × 12 h
UO <0.5 mg/kg/h × 12 h?
Anuria × 12 h
Risk
Injury
Failure
Loss
ESRD ESRD >3 months
Irreversible AKI or persistent
AKI -
 earliest time 
point for 
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of RRT
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Figure 1 | RIFLE Criteria for Diagnosis of AKI. Adapted with
permission from Lameire et al.16
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Whether this definition can provide a common clinical
classification for all cases of AKI with adequate prognostic
information remains to be prospectively validated.
EPIDEMIOLOGY
Determination of the prevalence of AKI is dependent on the
definition employed and is also dependent on methods used
for ascertainment of cases. It is possible that all studies of the
epidemiology of AKI underestimate the prevalence rate,
regardless of the clinical setting, as patients are rarely
universally screened for changes in estimated glomerular
filtration rate or urine output. The incidence of AKI also
varies with the clinical setting and studies have separately
addressed community-, hospital-acquired, sepsis-induced,
and ICU-associated AKI.
Community-acquired AKI
There have been relatively few systematic studies of the
epidemiology of community-acquired AKI and those that
have been accomplished report widely varying rates of AKI
occurrence, depending on the definition utilized and the
community. Overall, annual rates of the incidence of AKI
vary from 22 to 620/million population. The definitional
dependence of the incidence of community-acquired AKI is
illustrated by a British study in which annual incidence rates
using the need for renal replacement therapy as a definition
was 22/million population vs. 175/million population
using the definition of a serum creatinine 45.7 mg/dl
(4500 mmol/l).9 A similar study in Scotland reported an
annual incidence of 50/million population using the need for
renal replacement therapy compared with 102/million
population with a serum creatinine 45.7 mg/dl
(X500 mmol/l) and 620/million population using a serum
creatinine 43.4 mg/dl (X300 mmol/l).10 A community-based
study from the Madrid region reported an annual incidence
of 209/million population using a complex definition
accounting for baseline level of kidney function and the rate
of rise in serum creatinine.11 There has never been a
comprehensive community-based study of the incidence of
AKI in the US, although community-acquired AKI may
account for 1% of hospital admissions.12 In tropical settings,
the etiology of community-acquired AKI may vary, as
diarrheal illnesses, infectious diseases, and snakebites are still
common causes of AKI. Botanical nephrotoxins and alter-
native medical therapies also contribute to AKI in these
clinical settings. Natural disasters such as earthquakes with
resulting crush-syndrome victims contribute to local and
regional epidemics of AKI.
Hospital-acquired AKI
A number of recent studies have increased our understanding
of the incidence of AKI in hospitalized patients. Two recent
studies have used administrative and claims databases to
provide a national sample of the incidence of mortality of
AKI in the US.13,14 Both studies were large, with each study
evaluating more than 5 000 000 hospital discharges. Although
reported prevalence rates and mortalities differed between
the two studies, each study documented that the prevalence
of AKI in hospitalized patients steadily increased over time,
with a concomitant trend towards decreased mortality
(Figure 2). In evaluating these studies, it is worth noting
that those studies relied on the validity of utilizing the
International Classification of Diseases, 9th revision, Clinical
Modification Codes (ICD-9-CM) for AKI. The performance
characteristics of the ICD-9-CM codes for AKI were
compared with serum creatinine-based definitions of AKI
in nearly 100 000 discharges from three Boston hospitals.15
There is a very high specificity (97.7%) for AKI with only
modest sensitivity (35.4%). Thus, administrative and claims
database-based evaluations of the prevalence of AKI in
hospitalized patients possibly severely underestimate mor-
bidity, mortality, and cost associated with AKI. The increase
in the prevalence of hospital-acquired AKI over time parallels
the increased prevalence of sepsis in hospitalized patients, a
major contributor to AKI in this setting.
Several single-center studies have reported that AKI occurs
in 5–7% of hospitalized patients.16 These data suggest that
hospital-acquired AKI exceeds the prevalence of a commu-
nity-acquired AKI 5–10-fold and that the major causes of
hospital-acquired AKI are changing. The incidence of post-
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Figure 2 | AKI: changing prevalence and mortality using
nationally-represented databases. (a) Increasing prevalence of
hospital-associated AKI. Adapted with permission from Xue et al.13
(b) Dialysis mortality with hospital-associated AKI. (m) AKI; (&) AKI
requiring dialysis. Adapted with permission from Waikar et al.14
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operative AKI is decreasing, whereas newer etiologies,
including HIV nephropathy, AKI after solid organ trans-
plantation, and after cardiac resuscitation are increasing.
Similarly, although the incidence of AKI because of antibiotic
use is declining, cases of hospital-acquired AKI owing to the
use of nonsteroidal anti-inflammatory drugs, angiotensin-
converting enzyme-inhibitors, chemotherapeutic agents, and
antiviral agents is increasing. Of interest, the prevalence of
acute or chronic kidney injury appears to be increasing
globally as the prevalence of chronic kidney disease increases.
In the two previously mentioned national samples from
administrative and claims data in the US, patients with
chronic kidney disease were three times as likely to develop
AKI. In a recent study from China, acute or chronic kidney
injury accounted for nearly 36% of biopsied AKI cases.17
Obstetric causes of hospital-acquired AKI, although still
prevalent in some environments, such as in India, are also
declining.18
Sepsis-induced AKI
In the US, sepsis accounts for approximately 750 000 hospital
admissions annually, with an overall mortality rate of
approximately 30%. Half of these patients require ICU
admission. In the US, the incidence of sepsis-related hospital
admissions appears to be rising at a rate between 1.5 and 8%
per year.19 and international epidemiologic studies suggest
that sepsis now accounts for 17% of all medical ICU
admissions. The incidence of AKI is increasing in parallel to
the incidence of sepsis.19 Kidney injury among the elderly as
a complication of sepsis is especially common; of the 6% of
ICU patients who develop AKI, the median age is 67, with
30% of these patients having pre-existing renal dysfunction.
The dominant risk factor for AKI among hospitalized
patients is sepsis, occurring in about half of kidney failure
in the ICU setting.20
A stepwise increase in AKI occurs as patients progress
from sepsis to septic shock. Thus, AKI occurred in 19 of
patients with sepsis, 23 with severe sepsis, and 51% with
septic shock with positive blood cultures.21 Though recent
advances in critical care management have improved overall
ICU survival, the same cannot be said for the critically ill with
AKI. Even in patients not requiring dialysis, AKI worsens
prognosis in critical illness; when dialysis is required, the ICU
mortality rises to 45–80%. Although the development of AKI
clearly is a marker of disease severity and adverse prognosis,
the extent to which the development of AKI actually
contributes to other organ system failure is an area of active
inquiry. Critically ill patients with pre-existing end-stage
renal disease have a better prognosis than when AKI develops
during sepsis, suggesting that the outcome is associated with
systemic disease in addition to kidney dysfunction itself.22
ICU-associated AKI
Development of AKI occurs frequently in the ICU setting.20
Consistent with the complexity of their disease state, a
plethora of studies have indicated that mortality ranges
between 23 and 79% in this patient population. Given the
excess mortality rates, much effort has been placed on
accurately predicting in-hospital mortality in critically ill AKI
patients. Such prediction models are important for clinical
decision-making, quality improvement, and design of future
clinical trials. Studies to date have attempted to either
validate generic or disease-specific predictive instruments or
have derived new predictive models.23 However, most studies
have been developed from single centers and have examined
risk factors at a single point in time. Recently, the Program to
Improve Care in Acute Renal Disease, a registry of critically ill
patients with AKI across multiple US clinical sites, developed
models for prognostic stratification and risk adjustment for
mortality after AKI. To extend previously published work,
this analysis provided separate predictive models at three
time points during the course of AKI (day of AKI diagnosis,
day of nephrology consultation, and day of initiation of renal
replacement therapy). A striking feature of this cohort is the
remarkable differences in patient characteristics, processes of
care, and outcomes across clinical sites.23 Table 2 demons-
trates significant predictors of mortality using time-depen-
dent covariates. The clinical and research applicability of this
model needs to be tested in future studies.
Dysmetabolism in AKI
Critical illness leads to significant derangements in the
metabolic milieu. Furthermore, the dysmetabolism accom-
panying critical illness is exacerbated in AKI by loss of kidney
homeostatic function (Figure 3). These metabolic pathways
represent potential therapeutic targets for improving out-
comes. Severe illness of almost any etiology is accompanied
by a generalized host inflammatory response, referred to as
the systemic inflammatory response syndrome. Central to
this process is the release of a cascade of potent inflammatory
mediators into the systemic circulation, followed temporally
by a compensatory anti-inflammatory response. The dys-
regulation of the inflammatory response in septic and
critically ill patients has been implicated as an important
mechanism underlying the development of multiple organ
system dysfunction, septic shock, and death.21 In critically ill
Table 2 | Predictors of mortality using time-dependent
covariates
Parameter
Cox model (modified with permission
from Chertow et al.23) RR 95% CI
Age (per decade) 1.13 1.01–1.26
Sepsisa 1.87 1.33–2.63
CNS failurea 4.58 3.30–6.35
Liver failurea 1.90 1.34–2.71
Hematologic failurea 1.46 1.01–2.10
Dialysisb 1.79 1.21–2.66
CI, confidence interval; CNS, central nervous system; RR, relative risk.
aSepsis status and organ system failure updated daily, last value carried forward
where missing.
bDialysis status carried forward after initiation.
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patients with AKI, pro- and anti-inflammatory cytokines are
simultaneously markedly elevated, in the presence or absence
of sepsis, and associated with significant and clinically
meaningful increases in mortality risk.24 Critically ill patients
with AKI also have impaired monocyte cytokine production
in a pattern that closely resembles other critically ill patients
without AKI. These studies suggest that strategies designed to
reduce inflammation in critically ill patients with established
AKI should be attempted with caution so as not to exacerbate
risk of infectious complications.
Hyperglycemia, along with other aspects of insulin
resistance predict death and morbidity in the critically ill
and are hallmarks of the so-called ‘diabetes of injury.’
Intensive insulin therapy designed to maintain blood glucose
at or below 110 mg/dl can reduce morbidity and mortality in
a surgical ICU and more recently in a medical ICU.25,26 AKI
patients may be even more likely to develop insulin resistance
owing to additive effects of loss of kidney metabolic function,
as the kidney plays an important role in glucose homeostasis.
Consistent with these observations, critically ill patients with
established AKI have significant insulin resistance, which is
associated with mortality.27 Whether or not hyperglycemia
and/or hyperinsulinemia contribute directly to adverse events
in critically ill patients with AKI or are simply a marker of
metabolic injury severity has not been adequately established.
The dysregulated inflammatory response increases
oxidative stress in patients with AKI. Furthermore, oxidative
stress is an important pathogenic mechanism in the
development of ischemic and toxic renal tubular injury.
Kidney disease itself is now recognized as an additional
stimulus for increased oxidative stress. Consistent with these
observations, several recent studies indicate that critically ill
patients with AKI manifest a marked increase in oxidative
stress biomarkers.28,29
CONCLUSION
Nephrologists and intensivists are currently making a
concerted effort to arrive at standardized terminology and
classification of AKI. As a result, concepts concerning the
lexicography, definitions, and epidemiolology of AKI are
changing. Recent studies have dramatically advanced our
understanding of the epidemiology and natural history of
AKI, particularly in the hospital and ICU setting. Data
indicate that small changes in kidney function have
important prognostic implications, that the prevalence of
AKI is increasing, and that associated mortality may be
declining. Recent data also emphasizes that in critically ill
patients with AKI, dysmetabolism (including dysregulated
inflammation, insulin resistance, and increased oxidative
stress) are exacerbated by the loss of kidney homeostatic
function. Increasing knowledge concerning the natural
history of AKI, particularly in the context of standardized
definitions and classification, are critical for improved
clinical decision-making, assessing processes of care, develop-
ing effective prognostication tools, and for the design of
future clinical trials.
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